Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018



SAN DIEGO, March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018, after the market close.  Pfenex management will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the financial results and provide a business update.

Pfenex logo (PRNewsFoto/Pfenex)

Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call.  A replay of the conference call will be available approximately one hour after the call until March 22, 2018.  To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10117964.  The conference call will also be available as a webcast.  To access the webcast link please log on to www.pfenex.com (http://www.pfenex.com).

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com), our investor relations website (http://pfenex.investorroom.com), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.  We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information.  Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.

 

SOURCE Pfenex Inc.


These press releases may also interest you

at 21:00
Shenzhen International UAV Expo - AirMap announced today that its UTM services have been selected by TopXGun to be integrated into the company's industry-leading autopilot systems for drones. AirMap services will significantly enhance the TopXGun...

at 20:59
Randall Stephenson, AT&T Inc.* chairman and chief executive officer, and John Stephens, AT&T Inc. senior executive vice president and chief financial officer spoke today at the Wells Fargo Securities 2018 Telecom 5G Forum. They discussed the recent...

at 19:15
Wix.com Ltd. ("Wix"), a leading global web development platform, today announced the pricing of $385 million aggregate principal amount of 0% Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified...

at 18:51
The 15th annual International Fotona Weekend, organized together with the 8th Laser and Health Academy Symposium, took place at the end of May in Portoroz, Slovenia. There was a record 100+ presentations and 700+ participants from 56 different...

at 18:24
In an effort to accelerate features and offerings of the Vaultbank Platform - currently in beta mode - Vaultbank, an innovative financial services company headquartered in San Francisco, has opened an office in India, hired 16 engineers and partnered...

at 18:15
McFadyen Digital, the leading ecommerce and online marketplace agency, has been named the global System Integrator Partner of the Year at the 2018 Marketplace & Platform Summit by Mirakl, held June 7th in Paris, France. The award punctuates a...




News published on 8 march 2018 at 16:15 and distributed by: